ArticlePloS one2025
Predicting the axillary lymph node tumor burden in breast cancer patients using ultrasonic radiomics nomogram model.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and validation of a novel nomogram predicting axillary lymph node metastasis among breast cancer patients in Egypt.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAssessing axillary lymph node (ALN) tumor burden (low burden: < 3 positive ALNs; high burden: ≥ 3 positive ALNs) preoperatively is essential for guiding treatment strategies. This study aimed to develop a radiomics-based nomogram by integrating clinical data, serologic markers, ultrasound imaging features, and ultrasound-derived radiomics features to predict axillary lymph node metastatic burden in breast cancer.
methodsA study was conducted on 234 breast cancer patients. Univariate and multivariate logistic regression analyses were used to identify independent risk factors from ultrasound imaging and clinical pathology, constructing a clinical model. Radiomics features were extracted from ultrasound images, and the best features were selected using the Least Absolute Shrinkage and Selection Operator (LASSO) algorithm to construct the Radiomics score. The Radiomics nomogram model was built by combining the Radiomics score and independent risk factors from the clinical model. The performance of the clinical model, radiomics model, and combined model in predicting axillary lymph node tumor burden was evaluated. Model performance was assessed by discrimination, calibration curves, and decision curves.
resultsResults showed that US-reported ALN status and CA153 were independent risk factors for high ALN tumor burden. The radiomics nomogram demonstrated good calibration and discrimination, with an area under the ROC curve of 0.815 (95% CI, 0.755-0.876) for the training set and 0.808 (95% CI, 0.678-0.938) for the testing set. Furthermore, compared to the clinical model and radiomics model, The differences in AUC between the nomogram model and the clinical model, as well as between the nomogram model and the radiomics model, were not statistically significant (nomogram model vs. clinical model: P = 0.2078; nomogram model vs. radiomics model: P = 0.4161). But the nomogram model provided greater net benefit for all patients in the probability threshold range of 0.05-0.70.
conclusionsThis study highlights the potential of an ultrasound-based radiomics nomogram as a robust and non-invasive predictive tool for evaluating ALN tumor burden, offering valuable guidance for personalized treatment planning in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.